Exact Sciences

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Exact Sciences excels in Q4, eyes international growth and innovation

Exact Sciences delivered a robust financial performance in Q4 2022, driven by revenue growth and advancements in precision oncology.
The company's focus on compliance improvements, international expansion, and new product development positions it for future success.
Challenges in profitability, domestic market growth, and product validation are being addressed through strategic investments and operational enhancements.
Opportunities in international markets, Medicare coverage expansion, and legislative advantages provide avenues for sustained growth and market leadership.

Exact Sciences reports record-breaking Q1 revenue and anticipates strong growth opportunities

Exact Sciences' Q1 performance reflects strong revenue growth and strategic advancements in product development. The company's focus on partnerships, innovation, and market expansion positions it well for sustained growth. With a positive outlook for the year and a clear strategic direction, Exact Sciences is poised for continued success.

Exact Sciences excels in Q2 earnings, eyes international expansion

Exact Sciences delivered robust financial performance in Q2 2023, driven by revenue growth and innovative test developments.
While facing challenges like seasonality and capacity issues, the company is well-positioned to capitalize on opportunities for expansion and market penetration.
Strategic partnerships, positive test feedback, and revenue guidance raise optimism for Exact Sciences' future growth trajectory.
Focus on efficiency, innovation, and international expansion underscores the company's commitment to long-term success and market leadership.

Exact Sciences excels in Q3, eyes growth through innovation and partnerships

Exact Sciences delivered strong Q3 results, showcasing robust revenue, EBITDA, and Cologuard milestones, while addressing analyst inquiries on market strategies and growth sustainability.
The company's strengths in product innovation, strategic partnerships, and financial prudence position it well for future expansion and market leadership.
Challenges in capacity constraints, market dynamics, and regulatory compliance require proactive management strategies to mitigate risks and drive sustainable growth.
Opportunities in market expansion, product development, and strategic initiatives offer avenues for Exact Sciences to capitalize on its strengths and navigate challenges effectively.

Exact Sciences reports record-breaking 2023 results and eyes international growth

Exact Sciences delivered exceptional results in 2023, with strong financial performance and strategic growth initiatives. The company's focus on innovation, partnerships, and market expansion positions it well for sustained success.
Challenges in reimbursement pathways and market dynamics require careful navigation and strategic planning. Opportunities in expanding market reach, leveraging technology, and advancing key programs offer avenues for future growth.
With a clear focus on precision oncology, international expansion, and enhancing screening effectiveness, Exact Sciences is poised for continued success. Strategic investments in growth areas and operational efficiencies demonstrate a commitment to long-term value creation.

Exact Sciences reports robust Q1 earnings, eyes growth opportunities

Exact Sciences' strong Q1 performance and strategic initiatives position the company for continued growth in cancer eradication efforts and revenue generation.
While facing challenges such as cash flow management and regulatory uncertainties, the company's focus on innovation and market penetration presents opportunities for future success.
With a positive outlook for the year ahead and a commitment to addressing market challenges, Exact Sciences remains poised for sustained growth and competitive advantage.

Exact Sciences excels in Q2 with record screening and revenue

Exact Sciences delivered impressive financial performance in Q2 2024, with record screening numbers and revenue growth.
Their focus on innovation and product launches indicates a commitment to advancing cancer screening technology.
While facing challenges in a competitive market, the company's strategic planning and confidence in future success position them well for growth.

Exact Sciences reports 13% revenue growth in Q3 2024

Exact Sciences delivered solid Q3 performance with revenue growth and margin expansion, despite facing challenges in Cologuard adoption and Precision Oncology transition.
The company is optimistic about growth prospects in 2025, focusing on key initiatives like Cologuard Plus launch and achieving higher EBITDA margins by 2027.
With a clear roadmap for addressing challenges and leveraging growth opportunities, Exact Sciences aims to drive sustainable revenue growth and profitability in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Exact Sciences (EXAS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Amazon

Snowflake

More than halfway through the year and the stock market is not done setting new all-time highs. With inflation ticking lower for the first time in four years possibly paving the way for interest rate cuts to arrive sooner than expected, investors are bidding up shares.

Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns

Sarepta Therapeutics

United Therapeutics

In June, we profiled biotech exchange-traded fund (ETF) SPDR S&P Biotech ETF (XBI) amid a historically bullish month.

3 Biotech Stocks You Should Know About

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, announced today that it awarded a total of $1.5 million to 28 organizations through its Funding Opportunities for CRC Screening Uptake Strategies (FOCUS) Program. Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making health care more accessible, with a focus on medically underserved populations. CRC is one of the most preventable and treatable can.

Exact Sciences Awards Grants to 28 Organizations Focused on Increasing Colorectal Cancer Screening

Exact Sciences is facing a barrage of headwinds. The company's financial results haven't been good of late.

This Cathie Wood Growth Stock Could Soar by 93%, According to Wall Street

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. Second quarter 2024 webcast & conference call details Date: We.

Exact Sciences schedules second quarter 2024 earnings call

Guardant Health Inc

Illumina

The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected to continue expanding, with projections indicating it could reach approximately $390.65 billion, growing at a compound annual growth rate (CAGR) of around 8.20% from 2024 to 2030.

The 3 Best Personalized Medicine Stocks to Buy in July 2024

ST. LOUIS--(BUSINESS WIRE)--On June 28, Geneoscopy filed a lawsuit asserting multiple claims for damages against Exact Sciences in federal court in the District of Delaware.

Geneoscopy Files Counterclaims Against Exact Sciences

Flutter Entertainment PLC

Pacific Biosciences of California

We are almost halfway through 2024, and the stock market is putting on a masterclass performance. The S&P 500 is up 12% year-to-date after rising 23% last year.

Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns

MongoDB

Software businesses like MongDB were a drag on the market in May. Medical testing company Exact Sciences also took a sharp turn lower.

Is It Time to Buy May's Worst-Performing Nasdaq Stocks?

Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?

Why Is Exact Sciences (EXAS) Down 17.5% Since Last Earnings Report?

Inhibrx Biosciences Inc

Agilent Technologies

Teladoc

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 4 Health Care Stocks That Are Preparing To Pump This Month - Inhibrx Biosciences (NASDAQ:INBX)

Exact Sciences (EXAS) has numerous competitors, given the large market for colorectal cancer screening.

Exact Sciences (EXAS) Witnesses Rising Expenses, Competition

Exact Sciences' (EXAS) latest study research result shows commitment to innovation and strategies that expand access to effective cancer screening and diagnostic tools for patients.

Exact Sciences (EXAS) to Showcase Favorable Research Outcome

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that company management will participate in the following conferences and invited investors to participate by webcast. William Blair 44th Annual Growth Stock Conference, Chicago Presentation on Tuesday, June 4, 2024 at 1:40 p.m. ET Jefferies Healthcare Conference, New York Fireside chat on Wednesday, June 5, 2024 at 11:00 a.m. ET Goldman Sachs 45th An.

Exact Sciences to Participate in June Investor Conferences

Joby Aviation

Riot Blockchain

With the S&P 500 sitting just a few points below setting a new all-time high, the bull market that began in 2022 is still snorting. Although a correction or even a bear market will eventually happen, the market is content to run higher.

Bull Market Blastoff: 3 Stocks Targeting 56% to 91% Returns

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 10 abstracts highlighting the breadth and depth of the company's screening and diagnostic portfolio at the American Society of Clinical Oncology® (ASCO®) Annual Meeting, taking place May 31 – June 4, 2024, in Chicago, Ill. Presentations will include new data confirming both the predictive and prognostic value of the Oncotype DX Breast Recurrence Score® t.

Exact Sciences Demonstrates Continued Leadership in Early Cancer Diagnosis and Improved Health Outcomes for Patients with Multiple Data Presentations at ASCO®

ST. LOUIS--(BUSINESS WIRE)--The court dismissed Exact Sciences' ‘781 patent infringement claim against Geneoscopy.

Court Dismisses Exact Sciences' ‘781 Patent Infringement Claim Against Geneoscopy

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that the company has been certified as a 2024 Great Place To Work® for the sixth consecutive year. The certification is based on the results of a confidential employee survey to U.S.-based employees, providing an unbiased evaluation of the company's work environment, culture, and leadership. This year, 85% of employees called Exact Sciences a Great Place To.

Exact Sciences Earns 2024 Great Place To Work® Certification™

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that a District Court judge denied in part Geneoscopy's (defendant) motion to dismiss a patent infringement lawsuit filed by Exact Sciences (plaintiff) in the United States District Court for the District of Delaware. This ruling paves the way for Exact Sciences to seek relief for Geneoscopy's future infringement and false advertising. Exact Sciences.

Court Ruling Enables Exact Sciences to Proceed with Lawsuit against Geneoscopy

Prime Medicine Inc

Verve Therapeutics

The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.

Wall Street Favorites: 3 Cathie Wood Stocks With Strong Buy Ratings for May 2024

LONDON--(BUSINESS WIRE)--Exact Sciences, a leading provider of cancer screening and diagnostic tests, today announced that the UK's National Institute for Health and Care Excellence (NICE) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to more effectively target chemotherapy treatment for women who have hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), early-stage breast cancer involving up to three positive nodes and.

The National Institute for Health and Care Excellence (NICE) Recommends Use of Exact Sciences' Oncotype DX® Test to Help Guide Chemotherapy Decisions for Node-positive Breast Cancer Patients

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Exact Sciences (EXAS) Q1 Revenues Rise Y/Y, Gross Margin Down

Exact Sciences (EXAS) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago.

Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates

Exact Sciences stock tumbled late Wednesday after the Cologuard-maker reported wide losses, though sales came in ahead of expectations.

News for Exact Sciences Stock (EXAS)